Vaccination, Immunisation and Immune Disorders | Nursing Microbiology

Semester 1 — Microbiology — Chapter 10 — Unit 2: Infection and Immunity

Vaccination is a major preventive-health intervention built on adaptive immune recognition and memory. Nurses also need to understand the broad categories of altered immune function, including allergy, autoimmunity and immunodeficiency. This chapter explains the science and communication principles without giving an immunisation schedule or prescribing advice that may become outdated.

1. Vaccination and immunisation

Vaccination means administering a vaccine to stimulate an immune response to an antigen or instructions for producing an antigen. Immunisation refers more broadly to the process of becoming protected, which may follow vaccination or other immunological mechanisms. Protection is not necessarily complete and may vary with age, immune function, exposure and circulating pathogen variants.

In practice, a vaccination record documents a dose given, not proof that every individual achieved the same level of protection. Nursing documentation should capture the correct product and administration information required by the local programme. Eligibility and spacing requirements follow the current official schedule, not an outdated teaching handout.

2. Active versus passive immunity

Active immunity develops when a person’s immune system responds to an antigen through infection or vaccination, potentially producing memory. Passive immunity occurs when preformed antibodies are transferred—for example, maternal antibodies or certain medically administered antibody products. Passive protection can be rapid but is generally temporary because transferred antibodies are broken down.

These terms refer to the source of the immune response, not its quality or safety. Both have roles in medicine. A nurse should not confuse an immune globulin product with a conventional active vaccine or assume one replaces the other. Patient-specific decisions depend on the exposure, product indications and professional guidance.

3. Primary and secondary immune responses

A first encounter with an antigen activates naive antigen-specific lymphocytes and initiates a primary immune response. After memory is established, later exposure to related antigens may trigger a more rapid or robust response. Boosters may restore or increase protection for some vaccines when immune responses decline or when further priming is needed.

Not every vaccine produces lifelong protection, and immunity may differ for infections with rapid antigenic change. The timing and need for boosters should be taken from current national recommendations. A prior antibody result is not universally an accepted substitute for a complete vaccine record.

4. Live attenuated and inactivated vaccines

Live attenuated vaccines use weakened organisms capable of limited replication under controlled conditions, whereas inactivated vaccines contain organisms that cannot replicate. Live platforms may stimulate several components of immunity, but some are unsuitable for particular immunocompromised patients. Inactivated platforms do not reproduce as pathogens and may need additional doses depending on formulation and response.

This comparison must not be simplified into ‘live is always better’ or ‘inactivated never causes reactions’. Each product has particular benefits, contraindications, precautions and storage requirements. Nurses review the approved product information and current guidance; neither platform is chosen from a generic comparison table alone.

5. Subunit, toxoid and conjugate approaches

Subunit vaccines contain selected microbial antigens rather than whole organisms. Toxoid vaccines contain inactivated bacterial toxins designed to stimulate protective responses against toxin effects. Conjugate vaccines chemically link certain polysaccharide antigens to proteins to improve immune responses, especially in age groups where isolated polysaccharides can be less effective.

A vaccine targeting a toxin can prevent toxin-mediated illness without necessarily preventing every instance of microbial colonisation. Similarly, coverage of particular serotypes does not mean the product protects against all related organisms. Clear explanations should identify the specific outcome the vaccine aims to prevent.

6. Nucleic-acid and viral-vector platforms

Messenger RNA vaccines provide instructions that host cells temporarily use to produce a target antigen, stimulating immune recognition. Viral-vector vaccines use a modified vector to deliver genetic instructions, while other vaccine platforms use recombinant proteins or whole inactivated agents. These methods differ in manufacturing, immune activation and handling requirements.

Vaccine platforms do not alter a person’s genome simply because they use genetic instructions. Scientific assessment of safety and effectiveness is product-specific and continues after authorisation. Patient education should avoid unsupported universal claims—positive or negative—about whole categories.

7. Adverse events versus contraindications

A temporally associated event after vaccination is not automatically caused by the vaccine. Expected reactions such as local soreness or short-lived systemic symptoms differ from severe, rare adverse events. Causality assessment considers background rates, biological plausibility, timing and other evidence. A contraindication is a specific condition where a product should not be administered according to approved guidance.

Nursing practice includes screening, informed discussion, safe administration by trained staff, observation according to policy, and timely documentation and reporting through the relevant vaccine-safety system. Decisions after a previous severe reaction require appropriate clinical review rather than reassurances or assumptions based on an internet summary.

8. Hypersensitivity and allergy

Hypersensitivity describes an excessive or inappropriate immune response that can contribute to tissue injury. The classic Gell and Coombs scheme describes four broad mechanisms: immediate IgE-mediated reactions (type I), antibody-mediated cellular injury (type II), immune-complex mechanisms (type III) and T-cell-mediated delayed responses (type IV). Actual diseases may involve more than one mechanism.

Anaphylaxis is a medical emergency and requires immediate response under institutional protocol. This chapter does not provide drug-dose instructions. Nurses must know local emergency pathways and distinguish a documented allergy from an unverified historical ‘intolerance’ label, which can affect patient care.

9. Autoimmune disease and tolerance

Immune tolerance normally limits damaging responses against the body’s own tissues. Autoimmune disorders occur when immune mechanisms contribute to injury of self tissues. They may be organ-focused or systemic. Mechanisms can involve antibodies, T lymphocytes, genetic susceptibility and environmental factors. No single immune laboratory marker independently confirms all autoimmune conditions.

Students should not infer that every inflammatory symptom is autoimmune or that a positive autoantibody assay always proves disease. Clinical evaluation and specialised criteria are important. Immunomodulatory medicines may change infection risk, and nurses coordinate appropriate monitoring according to the treatment plan.

10. Immunodeficiency and vulnerability

Primary immunodeficiencies are linked to intrinsic defects in immune components, often genetic, while secondary or acquired immune deficiencies may arise from conditions, infections, medicines or other factors. Manifestations vary: some patients experience recurrent or unusual infections; others have immune dysregulation. Not every infection indicates immunodeficiency.

Vaccination suitability and timing can require specialist advice in immune-compromised patients, particularly regarding live vaccines or responses to vaccination. Nursing responsibilities include recognising concerning changes, following protective measures and accurately reporting immunisation and medication history.

11. Ethical, practical vaccination communication

Good vaccine communication begins with the patient’s question, not a scripted lecture. Explain what the vaccine aims to prevent, the known common adverse effects, rare serious risks and the limitations of protection, using evidence appropriate to the specific product. Respect the patient’s circumstances and the applicable consent process. Avoid shaming, coercive claims or false certainty.

Storage, cold-chain documentation, administration technique and reporting requirements depend on the product and local programme. When a patient raises a concern about contraindications, refer to current authorised guidance or an appropriately qualified clinician rather than improvising a decision. Accurate records protect both patients and programmes.

Immune concepts compared

Case studies for nursing students

Case 1: Patient reports a previous allergic reaction to a vaccine

The nurse documents the exact event and seeks appropriate review before administration; not every post-vaccine symptom is a contraindication.

Case 2: Immunocompromised patient requests a live vaccine

The nurse avoids assuming suitability, reviews the current recommendations and consults the treating clinical team.

Case 3: Patient asks whether a vaccine guarantees no infection

Explain that protection is product- and person-specific and may target severe illness or other defined outcomes without eliminating all possible infection.

Clinical caution: This chapter explains concepts and cannot replace patient-specific diagnosis, product information, national schedules, institutional policies or qualified clinical supervision.

Self-assessment MCQs with explanations

1. Passive immunity involves?
   1. Antibody production by memory B cells only
   2. Bacterial growth
   3. Transfer of preformed antibodies
   4. Mutation

   Answer C: Transfer of preformed antibodies. Passive immunity provides antibodies without needing the recipient to mount the entire initial response.

2. A toxoid vaccine primarily targets?
   1. An inactivated toxin antigen
   2. Bacterial ribosomes
   3. Viruses only
   4. The skin barrier

   Answer A: An inactivated toxin antigen. Toxoid vaccines stimulate protection against specified toxins.

3. Which platform uses an attenuated replicating organism?
   1. Subunit
   2. Toxoid
   3. mRNA
   4. Live attenuated

   Answer D: Live attenuated. Live attenuated vaccines contain weakened organisms.

4. A serious event after immunisation is automatically caused by the vaccine?
   1. Yes
   2. No
   3. Only in adults
   4. Only after boosters

   Answer B: No. Temporal sequence alone does not prove causation.

5. Type I immediate hypersensitivity is often associated with?
   1. IgG only
   2. Platelets
   3. IgE-mediated responses
   4. Red cell morphology

   Answer C: IgE-mediated responses. IgE-mediated responses can trigger immediate allergic symptoms.

6. Which is a common feature of adaptive immune memory?
   1. Potentially faster response to later antigen exposure
   2. Complete immunity to all infections
   3. No lymphocyte involvement
   4. Lack of any cellular signals

   Answer A: Potentially faster response to later antigen exposure. Memory cells can facilitate improved recall responses.

7. Autoimmunity can involve?
   1. Only microbial toxins
   2. Only dehydration
   3. No immune cells
   4. Immune damage directed at self tissues

   Answer D: Immune damage directed at self tissues. Autoimmune mechanisms involve loss of tolerance or damaging immune recognition.

8. Immunodeficiency is always inherited?
   1. Yes
   2. No
   3. Only after vaccination
   4. Only in children

   Answer B: No. Secondary or acquired immunodeficiency can occur.

9. Should vaccine schedules be copied from an old textbook?
   1. Always
   2. Only for adults
   3. No, consult current official programme
   4. Only when a parent asks

   Answer C: No, consult current official programme. Eligibility and schedules change by time and jurisdiction.

10. Good counselling about vaccines includes?
    1. Accurate benefits, risks and limits
    2. Promise of zero risk
    3. Shaming hesitant patients
    4. Omitting informed consent

    Answer A: Accurate benefits, risks and limits. Clear, respectful, product-specific information supports informed decisions.

Chapter revision checklist

• Distinguish active and passive immunity and vaccination from immunisation: explain this without looking at notes.
• Describe major vaccine platform categories: explain this without looking at notes.
• Explain immune memory, primary response and booster concepts: explain this without looking at notes.
• Recognise general categories of hypersensitivity, autoimmunity and immunodeficiency: explain this without looking at notes.
• Practise evidence-based, person-centred vaccine communication and documentation: explain this without looking at notes.
• Redraw each diagram from memory, then evaluate the case-study conclusions.

References and further reading

1. OpenStax — Vaccines
2. OpenStax — Hypersensitivities
3. OpenStax — Immunodeficiency

Academic status: Original notes awaiting Faizan’s editorial and nursing review. Not independently peer reviewed.